122 related articles for article (PubMed ID: 11715353)
1. Modifying the natural history of atherosclerosis: the SECURE trial.
Lonn E
Int J Clin Pract Suppl; 2001 Jan; (117):13-8. PubMed ID: 11715353
[TBL] [Abstract][Full Text] [Related]
2. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
Lonn E; Yusuf S; Dzavik V; Doris C; Yi Q; Smith S; Moore-Cox A; Bosch J; Riley W; Teo K;
Circulation; 2001 Feb; 103(7):919-25. PubMed ID: 11181464
[TBL] [Abstract][Full Text] [Related]
3. Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.
Lonn EM; Yusuf S; Doris CI; Sabine MJ; Dzavik V; Hutchison K; Riley WA; Tucker J; Pogue J; Taylor W
Am J Cardiol; 1996 Oct; 78(8):914-9. PubMed ID: 8888665
[TBL] [Abstract][Full Text] [Related]
4. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
5. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
[TBL] [Abstract][Full Text] [Related]
6. ACE inhibitor inhibits atherosclerosis.
Harv Heart Lett; 2001 May; 11(9):6-7. PubMed ID: 11410954
[No Abstract] [Full Text] [Related]
7. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
[TBL] [Abstract][Full Text] [Related]
8. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering.
Azen SP; Qian D; Mack WJ; Sevanian A; Selzer RH; Liu CR; Liu CH; Hodis HN
Circulation; 1996 Nov; 94(10):2369-72. PubMed ID: 8921775
[TBL] [Abstract][Full Text] [Related]
9. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
10. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.
Hoogwerf BJ; Young JB
Cleve Clin J Med; 2000 Apr; 67(4):287-93. PubMed ID: 10780101
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
Gerstein HC; Bosch J; Pogue J; Taylor DW; Zinman B; Yusuf S
Diabetes Care; 1996 Nov; 19(11):1225-8. PubMed ID: 8908384
[TBL] [Abstract][Full Text] [Related]
12. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.
MacMahon S; Sharpe N; Gamble G; Clague A; Mhurchu CN; Clark T; Hart H; Scott J; White H
J Am Coll Cardiol; 2000 Aug; 36(2):438-43. PubMed ID: 10933355
[TBL] [Abstract][Full Text] [Related]
13. [Ramipril can do more. Halting progression of atherosclerosis].
MMW Fortschr Med; 2001 Sep; 143(35-36):45. PubMed ID: 11584530
[No Abstract] [Full Text] [Related]
14. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.
Mitrovic V; Klein HH; Krekel N; Kreuzer J; Fichtlscherer S; Schirmer A; Paar WD; Hamm CW
Z Kardiol; 2005 May; 94(5):336-42. PubMed ID: 15868362
[TBL] [Abstract][Full Text] [Related]
15. Future perspectives and implications.
Sleight P
Int J Clin Pract Suppl; 2001 Jan; (117):22-3. PubMed ID: 11715355
[TBL] [Abstract][Full Text] [Related]
16. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
17. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
[TBL] [Abstract][Full Text] [Related]
18. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on ramipril in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].
Scheen AJ
Rev Med Liege; 2000 Feb; 55(2):121-4. PubMed ID: 10769584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
